RAPT THERAPEUTICS, INC. (RAPT): Price and Financial Metrics

RAPT THERAPEUTICS, INC. (RAPT): $8.98

0.05 (+0.56%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add RAPT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#275 of 365

in industry

RAPT Price/Volume Stats

Current price $8.98 52-week high $27.35
Prev. close $8.93 52-week low $6.86
Day low $8.71 Volume 860,900
Day high $9.00 Avg. volume 1,268,603
50-day MA $15.91 Dividend yield N/A
200-day MA $17.93 Market Cap 312.49M

RAPT Stock Price Chart Interactive Chart >


RAPT THERAPEUTICS, INC. (RAPT) Company Bio


Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.


RAPT Latest News Stream


Event/Time News Detail
Loading, please wait...

RAPT Latest Social Stream


Loading social stream, please wait...

View Full RAPT Social Stream

Latest RAPT News From Around the Web

Below are the latest news stories about RAPT THERAPEUTICS INC that investors may wish to consider to help them evaluate RAPT as an investment opportunity.

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

Positive clinical and molecular effects observed, with improvements demonstrated in key exploratory efficacy endpoints - percent change in EASI, EASI-50, vIGA and pruritis NRS - at four weeksFurther deepening of response in percent change in EASI, EASI-50 and vIGA observed two weeks after end of treatmentSignificant changes in transcriptional profile of patients treated with zelnecirnon at Day 29, which were also significantly correlated with improvements in clinical efficacy measuresZelnecirnon

Yahoo | November 27, 2023

RAPT Therapeutics Inc Reports Increased R&D Expenses Amid Progress in Clinical Trials

Net Loss Widens in Q3 2023; Strong Cash Position to Support Operations Through Mid-2025

Yahoo | November 15, 2023

RAPT Therapeutics Reports Third Quarter 2023 Financial Results

Company maintains strong cash position of $184.8 millionSOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the third quarter and the nine months ended September 30, 2023. “We continue to ma

Yahoo | November 13, 2023

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI) - Median progression-free survival (PFS) of 6.3 months in PD-L1 positive patients at time of data cut off - Confirmed ORR of 50% in patients with PD-L1 high expression (TPS ≥50%) and 38% in patients with PD-L1 low expression (TPS 1-49%) - RAPT to host webcast conference call today at 10:00 am PT SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- RAPT

Yahoo | November 3, 2023

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in November: Guggenheim Healthcare Talks: 5th Annual I&I Confer

Yahoo | November 1, 2023

Read More 'RAPT' Stories Here

RAPT Price Returns

1-mo 3.70%
3-mo -63.86%
6-mo -45.97%
1-year -47.76%
3-year -58.88%
5-year N/A
YTD -63.86%
2023 25.51%
2022 -46.09%
2021 85.97%
2020 -28.47%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!